$YTENQ
YIELD10 BIOSCIENCE, INC. Stock $ytenq

$ytenq Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000112170224000046 Filed on May 15, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$450.0K	$300.0K
YoY Change		400.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.004M	$1.374M
YoY Change	20.0%	-19.08%
% of Gross Profit
Research & Development		$1.366M
YoY Change		-36.82%
% of Gross Profit
Depreciation & Amortization		$66.00K
YoY Change		-4.35%
% of Gross Profit
Operating Expenses	$2.004M	$1.374M
YoY Change	20.0%	-19.08%
Operating Profit	-$3.203M	-$2.440M
YoY Change	-12.65%	-35.79%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$35.00K	-$32.00K
YoY Change	150.0%	-277.78%
Pretax Income		-$2.472M
YoY Change		-34.64%
Income Tax
% Of Pretax Income
Net Earnings	-$3.238M	-$2.472M
YoY Change	-12.03%	-34.64%
Net Earnings / Revenue	-719.56%	-824.0%
Basic Earnings Per Share	-$5.04	-$4.77
Diluted Earnings Per Share	-$5.04	-$4.77
COMMON SHARES
Basic Shares Outstanding	642.5K shares	15.40M shares
Diluted Shares Outstanding	642.4K shares	518.5K shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments		$1.597M
YoY Change		-11.72%
Cash & Equivalents	$733.0K	$1.597M
Short-Term Investments
Other Short-Term Assets		$526.0K
YoY Change		-17.03%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$1.204M	$2.123M
YoY Change	-60.2%	-13.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$432.0K	$487.0K
YoY Change	-34.84%	-31.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$23.00K	$57.00K
YoY Change	-65.67%	3.64%
Total Long-Term Assets	$1.764M	$2.120M
YoY Change	-38.0%	-26.67%
TOTAL ASSETS
Total Short-Term Assets	$1.204M	$2.123M
Total Long-Term Assets	$1.764M	$2.120M
Total Assets	$2.968M	$4.243M
YoY Change	-49.44%	-20.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.369M	$1.646M
YoY Change	407.28%	232.53%
Accrued Expenses	$1.828M	$1.187M
YoY Change	32.95%	0.25%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due		$990.0K
YoY Change
Total Short-Term Liabilities	$7.669M	$6.210M
YoY Change	210.49%	173.57%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities		$1.346M
YoY Change		-29.93%
Total Long-Term Liabilities		$1.346M
YoY Change		-29.93%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.669M	$6.210M
Total Long-Term Liabilities		$1.346M
Total Liabilities	$9.206M	$7.556M
YoY Change	74.26%	80.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$419.9M	-$416.6M
YoY Change	3.12%	3.26%
Common Stock	$413.9M	$413.6M
YoY Change	1.44%	2.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.238M	-$3.313M
YoY Change
Total Liabilities & Shareholders Equity	$2.968M	$4.243M
YoY Change	-49.44%	-20.45%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$3.238M	-$2.472M
YoY Change	-12.03%	-34.64%
Depreciation, Depletion And Amortization		$66.00K
YoY Change		-4.35%
Cash From Operating Activities		-$903.0K
YoY Change		-66.14%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change		-100.0%
Cash From Investing Activities		$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		$1.211M
YoY Change		758.87%
NET CHANGE
Cash From Operating Activities		-$903.0K
Cash From Investing Activities		$0.00
Cash From Financing Activities		$1.211M
Net Change In Cash		$308.0K
YoY Change		-156.31%
FREE CASH FLOW
Cash From Operating Activities		-$903.0K
Capital Expenditures		$0.00
Free Cash Flow		-$903.0K
YoY Change		-66.26%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001121702
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6210000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4865000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1346000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1525000	usd
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	501357	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	501357	shares
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	300000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	60000	usd
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock
CY2024Q1	dei	Trading Symbol TradingSymbol	YTEN
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	642546	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1597000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1068000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0416666666666667
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	526000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	332000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	2123000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1400000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	47000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	264000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	487000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	548000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1529000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1653000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	57000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	42000	usd
CY2024Q1	us-gaap	Assets Assets	4243000	usd
CY2023Q4	us-gaap	Assets Assets	3907000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1646000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1202000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1187000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2010000	usd
CY2024Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1700000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	687000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	669000	usd
CY2024Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	990000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	984000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	6390000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	411929000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-265000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-414152000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2483000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3907000	usd
CY2024Q1	yten	Cost Of Revenue Research And Development Expenses CostOfRevenueResearchAndDevelopmentExpenses	1366000	usd
CY2023Q1	yten	Cost Of Revenue Research And Development Expenses CostOfRevenueResearchAndDevelopmentExpenses	2162000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1374000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1698000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	2740000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	3860000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2440000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3800000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-32000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	18000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-32000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	18000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2472000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3782000	usd
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.77
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.77
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-18.16
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-18.16
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	518534	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	518534	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	208323	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	208323	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2472000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3782000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	3000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-4000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	3000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2469000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3785000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	66000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	69000	usd
CY2024Q1	yten	Charge For Company Common Stock Match ChargeForCompanyCommonStockMatch	9000	usd
CY2023Q1	yten	Charge For Company Common Stock Match ChargeForCompanyCommonStockMatch	29000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	403000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	436000	usd
CY2024Q1	yten	Noncash Lease Expense Income NoncashLeaseExpenseIncome	124000	usd
CY2023Q1	yten	Noncash Lease Expense Income NoncashLeaseExpenseIncome	104000	usd
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	0	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-30000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	198000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-37000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	444000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	307000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-818000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	241000	usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1700000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
CY2024Q1	yten	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-161000	usd
CY2023Q1	yten	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-138000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-903000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2667000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	1991000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1982000	usd
CY2024Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1211000	usd
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2024Q1	yten	Proceeds From Sale Of Common Stock At The Market Offering ProceedsFromSaleOfCommonStockAtTheMarketOffering	0	usd
CY2023Q1	yten	Proceeds From Sale Of Common Stock At The Market Offering ProceedsFromSaleOfCommonStockAtTheMarketOffering	182000	usd
CY2024Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	41000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1211000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	141000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-3000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	312000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-547000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1332000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2620000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1644000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2073000	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	79000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2483000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	375000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	25000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	28000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	3000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2472000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-3313000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4400000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	424000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	30000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	41000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	12000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3782000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1143000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1597000	usd
CY2024Q1	yten	License Agreement Term LicenseAgreementTerm	P3Y
CY2024Q1	us-gaap	Payment For Management Fee PaymentForManagementFee	3000000	usd
CY2024Q1	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	2000000	usd
CY2023Q2	yten	Sale Of Stock Maximum Shares SaleOfStockMaximumShares	38817	shares
CY2023Q2	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	967000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1597000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1068000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	47000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	264000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1644000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1332000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	47000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	264000	usd
CY2024Q1	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	12000	usd
CY2023Q4	yten	Collateral Held Credit Card Amount CollateralHeldCreditCardAmount	35000	usd
CY2024Q1	yten	Collateral Held Credit Card Amount CollateralHeldCreditCardAmount	35000	usd
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;padding-right:4.5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of license and grant revenue and expenses during the reporting periods. Actual results could differ from those estimates.</span></div>
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, restricted cash, short-term investments and accounts receivable. The Company has historically invested its cash in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company’s investment policy which establishes a concentration limit per issuer.</span></div>
CY2024Q1	yten	Consideration Of License Fees To Be Paid ConsiderationOfLicenseFeesToBePaid	3000000	usd
CY2024Q1	yten	License Agreement Term LicenseAgreementTerm	P3Y
CY2024Q1	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	2000000	usd
CY2024Q1	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	2000000	usd
CY2024Q1	us-gaap	Deferred Revenue DeferredRevenue	1700000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	25068	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	10300	shares
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	540110	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	95396	shares
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	431000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	103000	usd
CY2024Q1	yten	Accrued Lease Cost AccruedLeaseCost	4000	usd
CY2023Q4	yten	Accrued Lease Cost AccruedLeaseCost	27000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	296000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	452000	usd
CY2024Q1	yten	Accrued Field Trials And Related Expenses Current AccruedFieldTrialsAndRelatedExpensesCurrent	125000	usd
CY2023Q4	yten	Accrued Field Trials And Related Expenses Current AccruedFieldTrialsAndRelatedExpensesCurrent	1032000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	331000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	396000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1187000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2010000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	403000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	436000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1819000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y4M9D
CY2022Q1	yten	Share Based Compensation Arrangement By Share Based Payment Award Additional Shares Authorized Percent ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent	0.05
CY2021Q1	yten	Share Based Compensation Arrangement By Share Based Payment Award Additional Shares Authorized Percent ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent	0.05
CY2023Q1	yten	Share Based Compensation Arrangement By Share Based Payment Award Additional Shares Authorized Percent ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent	0.05
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	20833	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	17843	shares
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	161000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	151000	usd
CY2024Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	165000	usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	217000	usd
CY2024Q1	us-gaap	Sublease Income SubleaseIncome	161000	usd
CY2023Q1	us-gaap	Sublease Income SubleaseIncome	159000	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	-165000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	-209000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0753
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0753
CY2016Q4	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	22213	sqft
CY2023Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	12000	usd
CY2024Q1	us-gaap	Contractual Obligation ContractualObligation	78000	usd
CY2023Q4	us-gaap	Contractual Obligation ContractualObligation	204000	usd
CY2024Q1	yten	Consideration Of License Fees To Be Paid ConsiderationOfLicenseFeesToBePaid	3000000	usd
CY2024Q1	yten	License Agreement Term LicenseAgreementTerm	P3Y
CY2024Q1	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	2000000	usd
CY2024Q1	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	2000000	usd
CY2024Q1	us-gaap	Deferred Revenue DeferredRevenue	1700000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	300000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	60000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	487000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	715000	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2023Q2	yten	Sale Of Stock Maximum Shares SaleOfStockMaximumShares	38817	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1	shares
CY2023Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	71.52
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	3067	shares
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	28000	usd
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	460953	shares
CY2024Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	593	shares
CY2024Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	540110	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	384372	shares
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001121702-24-000046-index-headers.html	Edgar Link	pending
0001121702-24-000046-index.html	Edgar Link	pending
0001121702-24-000046.txt	Edgar Link	pending
0001121702-24-000046-xbrl.zip	Edgar Link	pending
ex-311x20240331.htm	Edgar Link	pending
ex-312x20240331.htm	Edgar Link	pending
ex-321x20240331.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
yten-20240331.htm	Edgar Link	pending
yten-20240331.xsd	Edgar Link	pending
yten-20240331_cal.xml	Edgar Link	unprocessable
yten-20240331_def.xml	Edgar Link	unprocessable
yten-20240331_lab.xml	Edgar Link	unprocessable
yten-20240331_pre.xml	Edgar Link	unprocessable
yten-20240331_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$YTENQ
YIELD10 BIOSCIENCE, INC. Stock $ytenq

2024 Q2 Form 10-Q Financial Statement

#000112170224000046 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$YTENQ YIELD10 BIOSCIENCE, INC. Stock $ytenq

2024 Q2 Form 10-Q Financial Statement

#000112170224000046 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$YTENQ
YIELD10 BIOSCIENCE, INC. Stock $ytenq